Theradiag Reports 11% Year-on-Year Increase in Turnover, Reaching 9.9 Million Euros

Theradiag posted a turnover of 9.9 million euros as of September 30, 2023, up 11% year-on-year. The company specializing in the in vitro diagnosis of autoimmune diseases and Theranostic achieved a turnover of 3.2 million euros in the third quarter of 2023 compared to 2.6 million euros in the third quarter of 2022, i.e. growth of +20%, mainly supported by the In Vitro Diagnostic (IVD) activity which grew by +44%. The cash level at the end of September 2023 remains under control and reached more than 5.5 million euros.